DRP Journal

Discover Research Profit

Finance 

Halberd Corporation (OTC:HALB) Stock On Radar After Securing Contract from Defense Atomics Corporation

Scott Birndorf

On Wednesday, Halberd Corporation (OTC:HALB) was one of the companies to have come into focus among investors in a big way following a significant new announcement. It is likely that the company would be on the radars of many investors this morning owing to that. The company announced yesterday that through collaboration with Athena Telemedicine Partners (ATP) and Athena GTX, it had managed to bag a significant contract award commitment.

In the news release, Halberd Corporation announced that Defense Atomics Corporation had decided to engage the services of the teams at Athena/Halberd. Additionally, Defense Atomics would also finance advanced research, which would also include the FDA IND study, which leveraged the LDX technology from Halberd and WatchDawg monitoring technology from Athena. It was also revealed that Defense Atomics had also decided to deploy its own CRISPR/Nanotechnology stem cell treatment in at least 10 veterans in a government-backed study into the advanced protocol.

On the basis of the success of the CRISPR methodology in overseas patients, the study would aim to demonstrate the advantages of the technology in integration with the above-mentioned technologies of Halberd and Athena.

The Chief Executive Officer of Defense Atomics, Dr. Gabe Vlad, spoke about the latest developments as well. He noted that while the results from the CRISPR technology had been quite encouraging, it was a highly attractive opportunity to integrate the treatment methodology with the medication and monitoring technologies on offer from Halberd and Athena. William A. Hartman, the Chief Executive Officer of Halberd Corporation, noted that everyone at the company was looking forward to the expanded use of the company’s LDX technology. Moreover, the latest collaboration would also ensure that the results could be monitored through WatchDawg technology. It could be a good time for investors to consider adding the stock to their watch lists.